Literature DB >> 15628735

Severe interstitial pneumonitis secondary to pegylated interferon alpha-2b and ribavirin treatment of hepatitis C infection.

Valentin Fuhrmann1, Ludwig Kramer, Edith Bauer, Hermann Laferl, Gerhard Tucek, Gerhard Dekan, Peter Schenk.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15628735      PMCID： PMC7101913          DOI： 10.1007/s10620-004-9602-3

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  14 in total

1.  Severe exacerbation of asthma: a new side effect of interferon-alpha in patients with asthma and chronic hepatitis C.

Authors:  E J Bini; E H Weinshel
Journal:  Mayo Clin Proc       Date:  1999-04       Impact factor: 7.616

2.  Pegylated interferon and ribavirin-induced interstitial pneumonitis with ARDS.

Authors:  Sandra Abi-Nassif; Eugene J Mark; Robert B Fogel; Robert K Hallisey
Journal:  Chest       Date:  2003-07       Impact factor: 9.410

3.  An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group.

Authors:  P Bedossa; T Poynard
Journal:  Hepatology       Date:  1996-08       Impact factor: 17.425

4.  Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study.

Authors:  G Dusheiko; J Main; H Thomas; O Reichard; C Lee; A Dhillon; S Rassam; A Fryden; H Reesink; M Bassendine; G Norkrans; T Cuypers; N Lelie; P Telfer; J Watson; C Weegink; P Sillikens; O Weiland
Journal:  J Hepatol       Date:  1996-11       Impact factor: 25.083

5.  Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis.

Authors:  T Ishizaki; F Sasaki; S Ameshima; K Shiozaki; H Takahashi; Y Abe; S Ito; M Kuriyama; T Nakai; M Kitagawa
Journal:  Eur Respir J       Date:  1996-12       Impact factor: 16.671

6.  Interferon-related bronchiolitis obliterans organizing pneumonia.

Authors:  K Ogata; T Koga; K Yagawa
Journal:  Chest       Date:  1994-08       Impact factor: 9.410

7.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

Review 8.  Sarcoidosis after use of interferon for chronic hepatitis C: report of a case and review of the literature.

Authors:  V Tahan; F Ozseker; D Guneylioglu; A Baran; R Ozaras; A Mert; A C Ucisik; T Cagatay; D Yilmazbayhan; H Senturk
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

9.  Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy.

Authors:  K C Conlon; W J Urba; J W Smith; R G Steis; D L Longo; J W Clark
Journal:  Cancer       Date:  1990-05-15       Impact factor: 6.860

10.  Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus.

Authors:  T Ueda; K Ohta; N Suzuki; M Yamaguchi; K Hirai; T Horiuchi; J Watanabe; T Miyamoto; K Ito
Journal:  Am Rev Respir Dis       Date:  1992-07
View more
  5 in total

Review 1.  [Hepatopulmonary interactions].

Authors:  V Fuhrmann; P Tariparast
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-08-06       Impact factor: 0.840

Review 2.  Diagnosis and management of interstitial pneumonitis associated with interferon therapy for chronic hepatitis C.

Authors:  Fan-Pu Ji; Zheng-Xiao Li; Hong Deng; Hong-An Xue; Yuan Liu; Min Li
Journal:  World J Gastroenterol       Date:  2010-09-21       Impact factor: 5.742

3.  Interstitial pneumonitis associated with pegylated interferon-alpha 2a and ribavirin for chronic hepatitis C infection: a case report.

Authors:  Ozlen Atug; Hakan Akin; Yesim Ozen Alahdab; Berrin Ceyhan; Nurdan Tozun; Osman Ozdogan
Journal:  Cases J       Date:  2009-03-10

4.  Expectoration of large bronchial casts secondary to the treatment of chronic hepatitis C with pegylated interferon and ribavirin.

Authors:  Evaldo Stanislau Affonso de Araújo; Aleia Faustina Campos; Juliana Yamashiro; Evandro Sobrosa Mello; Teresa Takagaki; Antonio Alci Barone
Journal:  Clinics (Sao Paulo)       Date:  2010-07       Impact factor: 2.365

Review 5.  Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature.

Authors:  Serena Slavenburg; Yvonne F Heijdra; Joost P H Drenth
Journal:  Dig Dis Sci       Date:  2009-04-28       Impact factor: 3.199
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.